INJECTAFER
LOE Approachingferric carboxymaltose injection
NDAINTRAVENOUSSOLUTION
Approved
Jul 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
INJECTAFER (ferric carboxymaltose injection) is (iii) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron. First approved in 2013.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INJECTAFER is an intravenous iron replacement therapy containing ferric carboxymaltose, a ferric hydroxide complex stabilized by a carbohydrate polymer that releases iron for hemoglobin synthesis. It is indicated for iron deficiency anemia in patients who cannot tolerate or have failed oral iron therapy. The carboxymaltose polymer enables rapid, high-dose iron delivery with a favorable safety profile compared to older IV iron formulations.
LOE Approaching1.6 years to LOE
Product faces imminent loss of exclusivity in 1.7 years with moderate competitive pressure (15 competitors); commercial teams should expect portfolio transition planning and potential downsizing.
Mechanism of Action
(III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.